Business Wire

VidMob Raises $50 Million Series C to Accelerate Broad Adoption of its Platform for Intelligent Creative

24.2.2021 11:00:00 EET | Business Wire | Press release

Share

VidMob, the leading platform for Intelligent Creative, announced today that it has closed its Series C financing, raising $50 million in expansion capital from a group of funds, strategic investors, and influential companies in the creative technology space. The new round will support VidMob’s global expansion, new e-commerce initiatives, ongoing investments into advanced technology, and data science to help marketers maximize the value of advertising creative.

The new round includes participation from Adobe, the global leader in digital creativity software, Shutterstock, a leading global creative platform offering full-service solutions, high-quality content, and tools for brands, businesses and media companies, Drive by DraftKings, a venture capital firm investing in sports tech and entertainment, the Spruce House Partnership, Prefix Capital, BuildGroup, Interlock Partners, Macanta, and key industry and tech leaders like Michael Kassan, Nick Brien, and Thomas Tull, among others. César Melo, former president at Mondelez and PepsiCo, CEO at Foster Grant and VP at Colgate-Palmolive is also investing and joining the board as an advisor. When combined with previous rounds, the company has now raised nearly $100 million to expand on its groundbreaking platform for Intelligent Creative.

VidMob has pioneered AI to measure creative performance so marketers can optimize ad design for more efficient and impactful campaigns. VidMob’s Intelligent Creative platform unifies creative and data and connects brands to a global network of elite content creators trained on continuously updated best practices for every digital media channel and next-gen ad format. Originally focused on partnerships with the major social platforms, VidMob has expanded its distribution to include leaders in the programmatic web and CTV / OTT.

“Every other area of enterprise operations has been positively impacted by software platforms -- increasing efficiency and using data to bring intelligence to decision-making,” said Alex Collmer, the founder and CEO of VidMob. “This financing and these new relationships will be a powerful accelerant in our commitment to build and deploy a platform that helps marketers transform for the needs of the future, while respecting the irreplaceable role of human creativity and never losing sight of our mission to evolve creativity for the better.”

“We were blown away by the power of VidMob’s learning models for Intelligent Creative,” said Owen Van Natta of Prefix Capital, and former VP of Worldwide Business and Corporate Development at Amazon. “VidMob’s ‘services-in-the-loop’ model, coupled with the integration of their creative marketplace is a construct that is unrivaled in its learning capability.”

“Creative performance has gone unmeasured while the advertising industry has focused on technologies to measure return on media spend, said Lynda Clarizio, former President of Nielsen US Media and an investor in the financing. “VidMob’s platform for Intelligent Creative solves this long unmet need by offering marketers a scalable platform across media to measure the impact of creative on achieving campaign objectives and to optimize and improve the creative process.”

Former Executive Vice-Chairman of Omnicom Media Group, and previously global CEO of OMD, Aegis Media and MEC, Mainardo de Nardis, who also invested in the financing, added, “I was privileged to be part of a group of people who transformed the full-service advertising model, separating media from creative, at a time when advertisers demanded independent strategic media services. That was 30 years ago. Today, I am happy to be doing the exact opposite. It no longer serves marketers well to silo creative and media practices, both equally important in terms of optimization. The power of VidMob’s data-driven platform lies in its ability to unite media and creative, bringing together the many layers of the industry, from advertising platforms and brands to agencies.”

Consumer brand veteran César Melo added "as a commercial leader, I was always looking to create a more efficient content ecosystem in which faster, smarter, data-informed and more cost-effective content could be created to surround the consumer around the world and build brands differently. When I discovered VidMob while trying to do this at PepsiCo, I was blown away by the combination of talented human creativity and technology. And the more I see, the more I like. VidMob is creating a new category, “Intelligent Creative.”

VidMob is the only company to have earned a creative partner badge from every leading social and digital media platform, and its client roster includes many of the world’s most forward-thinking marketing organizations such as Johnson & Johnson and Colgate Palmolive.

A purpose-driven company since Day 1, VidMob donates a portion of every dollar earned to fund Intelligent Creative for non-profit organizations through its 501c(3) VidMob Gives. VidMob Gives has supported 84 NPOs across 63 countries. In 2020, VidMob Gives helped raise over $20 million in partnership with organizations including the CDC Foundation, UN Foundation, Equality Now and the Ronald McDonald House.

About VidMob

VidMob is the world’s first platform for Intelligent Creative that provides an end-to-end solution to help brands improve their marketing results by unifying creative and data. VidMob is the only company in the world to receive a certified creative marketing partner badge from every major social and digital platform. A portion of every dollar VidMob receives is used to fund pro bono creative services for non-profits through its 501(c)(3) VidMob Gives. Most recently, the company was included in Inc. magazine's annual list of the Best Workplaces for 2020 and VidMob received the 2020 Creative Intelligence Technology Innovation Award from Frost & Sullivan. Learn more about VidMob at www.vidmob.com and VidMob Gives at vidmob.gives.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tessa Flanagan
+44 (0)2036421124
Vidmob@teamgingermay.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release

Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release

Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release

Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye